The founding team previously built a CLIA-certified molecular test that earned an FDA Breakthrough Device Designation. Garde is their next diagnostic.
Chief Executive Officer
Rob founded Garde in 2025 to bring a more accurate, lower-cost prostate cancer test to market. He spent more than a decade in translational R&D, presented at the American Urological Association, and was part of the team that earned an FDA Breakthrough Device Designation and shipped a CLIA-certified molecular test.
Chief Scientific Officer
Martin has spent decades at the intersection of academic and translational prostate cancer research. He leads Garde's scientific direction and the design of the Garde Prostate Test.
Lead, Research & Development
Winnie co-founded Garde and leads research and development. At the team's prior company, she took a molecular diagnostic from concept through CLIA certification.
Lead, Biostatistics
Greg co-founded Garde and leads biostatistics, building the analytical foundation behind the supervised machine learning model that translates the molecular signal into clinical risk.
The founders previously shipped a high-complexity, CLIA-certified molecular test that earned FDA Breakthrough Device Designation. The underlying science spans hundreds of peer-reviewed publications.
Garde is built on independent IP with a more focused architecture, designed for lower cost and broader access.
Garde's advisors include leading urologists, oncologists, public health researchers, and biotech operators. They challenge the science, the clinical pathway, and the business model.
Consulting Advisor
A leading urologist at Sunnybrook Health Sciences Centre in Toronto. Dr. Klotz was named to the Order of Canada for his contributions to prostate cancer medicine and is widely regarded as one of the field's most influential clinicians.
Medical Advisor
Erica is a physician, researcher, professor, and former elected official. Her work spans preventive medicine, physician health, and population-scale health impact.
Advisor
Former Chief Executive Officer of Response Biomedical Corp. Barb sits on the advisory board of the Genome BC I-squared fund and brings deep operating and fundraising experience in Canadian biotech.
Clinical Study Partner
A urologic oncologist and surgeon scientist at the Vancouver Prostate Centre. Miles's clinical research program is focused on improving the diagnosis and treatment of localized prostate cancer.
Strategy Advisor
Stuart advises Garde on commercial strategy, partnership development, and go-to-market planning across reference labs and contract sales organizations.
Advisor
Former Chief Executive Officer of Ayogo Health and former board member of Innovate BC. Michael brings operating experience scaling digital health and connected-care products.
The Vancouver Prostate Centre, one of the leading translational prostate cancer research centers in North America, will conduct Garde's 600-patient validation study, led by Dr. Miles Mannas, urologic oncologist at the VPC.
The partnership combines Garde's molecular platform with the VPC's clinical expertise and patient cohort to rigorously evaluate test performance.
For investor inquiries, clinical collaboration, or media.